Prognostic Value of MicroRNA-21 in Epithelial Ovarian Carcinoma: A Protocol for Systematic Review and Meta Analysis

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2020 Dec 22

PMID 33350775

Citations 1

Authors

Kun Ji

Xiaohua Wang

Anqi Zhang

Hongwei Wen

Affiliations

Soon will be listed here.

Abstract

Backgroud: The expression of microRNA-21 has been shown to be associated with the prognosis in patients with malignant tumors. However, its prognostic value in epithelial ovarian carcinoma (EOC) remains controversial. This meta-analysis aimed to synthesize available data to clarify the association between microRNA-21 expression levels and clinical prognosis in EOC patients.

Methods: Eligible literatures were searched from Embase, Google Scholar, PubMed, Web of Science, Medline, Cochrane Library, China Scientific Journal Database, China National Knowledge Infrastructure, Chinese BioMedical Database and Wanfang Database to identify eligible studies. Papers in English or Chinese published from their inception to November 2020 will be included. Methodological quality for each eligible trial will be assessed by using the Newcastle-Ottawa Quality Assessment Scale. Odds ratios or hazards ratios with corresponding 95% confidence intervals were pooled to estimate the prognosis value of microRNA-21 by using Stata 14.0 and Review Manager 5.3 software.

Results: This study will provide a high-quality evidence-based medical evidence of the correlations between microRNA-21 expression and overall survival and disease-free survival.

Conclusion: The findings of this systematic review will show the effect of high expression of microRNA-21 on the prognosis of EOC patients.

Trial Registration Number: INPLASY2020110064.

Citing Articles

BPA Decreases PDCD4 in Bovine Granulosa Cells Independently of miR-21 Inhibition.

Sabry R, Williams M, Werry N, LaMarre J, Favetta L Int J Mol Sci. 2022; 23(15).

PMID: 35955412 PMC: 9368835. DOI: 10.3390/ijms23158276.

References

Jessmon P, Boulanger T, Zhou W, Patwardhan P . Epidemiology and treatment patterns of epithelial ovarian cancer. Expert Rev Anticancer Ther. 2017; 17(5):427-437. DOI: 10.1080/14737140.2017.1299575. View

Rooth C . Ovarian cancer: risk factors, treatment and management. Br J Nurs. 2013; 22(17):S23-30. DOI: 10.12968/bjon.2013.22.Sup17.S23. View

Jackson D, White I, Riley R . Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat Med. 2012; 31(29):3805-20. PMC: 3546377. DOI: 10.1002/sim.5453. View

Lheureux S, Gourley C, Vergote I, Oza A . Epithelial ovarian cancer. Lancet. 2019; 393(10177):1240-1253. DOI: 10.1016/S0140-6736(18)32552-2. View

Mahmoud E, Fawzy A, Elshimy R . Serum MicroRNA-21 Negatively Relates to Expression of Programmed Cell Death-4 in Patients with Epithelial Ovarian Cancer. Asian Pac J Cancer Prev. 2018; 19(1):33-38. PMC: 5844633. DOI: 10.22034/APJCP.2018.19.1.33. View

Li J, Jiang K, Zhao F . Icariin regulates the proliferation and apoptosis of human ovarian cancer cells through microRNA-21 by targeting PTEN, RECK and Bcl-2. Oncol Rep. 2015; 33(6):2829-36. DOI: 10.3892/or.2015.3891. View

Corrado G, Salutari V, Palluzzi E, Distefano M, Scambia G, Ferrandina G . Optimizing treatment in recurrent epithelial ovarian cancer. Expert Rev Anticancer Ther. 2017; 17(12):1147-1158. DOI: 10.1080/14737140.2017.1398088. View

Zhang W, Chen J, He G, Xu W, He G . Impact of mirna-21 on survival prognosis in patients with pancreatic cancer: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2020; 99(35):e22045. PMC: 7458261. DOI: 10.1097/MD.0000000000022045. View

Lin L, Chu H . Quantifying publication bias in meta-analysis. Biometrics. 2017; 74(3):785-794. PMC: 5953768. DOI: 10.1111/biom.12817. View

10.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

11.

Zhang W, Wei L, Luo R, Liu H, Chen J . The value of microRNA-21 as a biomarker for the prognosis of lung cancer: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2020; 99(33):e21483. PMC: 7437733. DOI: 10.1097/MD.0000000000021483. View

12.

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View

13.

Guyatt G, Oxman A, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P . GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336(7650):924-6. PMC: 2335261. DOI: 10.1136/bmj.39489.470347.AD. View

14.

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

15.

Chan J, Blansit K, Kiet T, Sherman A, Wong G, Earle C . The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer. Gynecol Oncol. 2014; 132(3):739-44. DOI: 10.1016/j.ygyno.2014.01.034. View

16.

Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M . Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015; 350:g7647. DOI: 10.1136/bmj.g7647. View

17.

Baez-Vega P, Echevarria Vargas I, Valiyeva F, Encarnacion-Rosado J, Roman A, Flores J . Targeting miR-21-3p inhibits proliferation and invasion of ovarian cancer cells. Oncotarget. 2016; 7(24):36321-36337. PMC: 5095003. DOI: 10.18632/oncotarget.9216. View

18.

Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMC: 1920534. DOI: 10.1186/1745-6215-8-16. View

19.

Duval S, Tweedie R . Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000; 56(2):455-63. DOI: 10.1111/j.0006-341x.2000.00455.x. View

20.

Paliwal N, Vashist M, Chauhan M . Evaluation of miR-22 and miR-21 as diagnostic biomarkers in patients with epithelial ovarian cancer. 3 Biotech. 2020; 10(3):142. PMC: 7046840. DOI: 10.1007/s13205-020-2124-7. View